This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Amgen Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Stevedat K La: Innovator in Cancer Treatment Formulations
Introduction
Stevedat K La is a notable inventor based in Moorpark, CA (US). He has made significant contributions to the field of pharmaceutical formulations, particularly in the treatment of cancer. His innovative work focuses on compounds that inhibit the MCL1 protein, which plays a crucial role in various hematological malignancies.
Latest Patents
Stevedat K La holds 1 patent for his invention titled "Formulations and dosages for administering a compound that inhibits MCL1 protein." This patent encompasses pharmaceutical formulations and aqueous solutions designed to treat cancer. The formulations include compounds of Formula I and may also contain cyclodextrin compounds, such as hydroxypropyl-β-cyclodextrin, along with buffers like glycine. The methods outlined in the patent specifically target hematological malignancies, including acute myelogenous leukemia, multiple myeloma, and non-Hodgkin's lymphoma.
Career Highlights
Stevedat K La is associated with Amgen Inc., a leading biotechnology company known for its innovative approaches to treating serious illnesses. His work at Amgen has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.
Collaborations
Throughout his career, Stevedat has collaborated with esteemed colleagues, including Ron C Kelly and Michael T Kennedy. These partnerships have fostered a collaborative environment that enhances the development of effective cancer treatments.
Conclusion
Stevedat K La's contributions to cancer treatment through his innovative formulations demonstrate his commitment to advancing medical science. His work not only highlights the importance of research in pharmaceuticals but also showcases the potential for new therapies in combating serious diseases.